LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

Home・Akcijų sąrašas・MannKind Corp

MannKind Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

3.48 2.96

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.3

Max

3.5

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-671K -17M
Pardavimai	-22M 90M
P/E Sektoriaus vid.	140.5 49.888
Pelnas, tenkantis vienai akcijai	-0.02
Pelno marža	-18.431
Darbuotojai	591
EBITDA	5.9M 3.4M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+142.56% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	223M 1.1B
Ankstesnė atidarymo kaina	0.52
Ankstesnė uždarymo kaina	3.48

Naujienos nuotaikos

By Acuity

47%

53%

144 / 344 reitingas Healthcare

MannKind Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-03 23:22; UTC

Uždarbis

Pagrindinės rinkos jėgos

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

2026-06-03 23:09; UTC

Karštos akcijos

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

2026-06-03 20:51; UTC

Uždarbis

Costco Reports 15% Sales Growth in May

2026-06-03 20:43; UTC

Uždarbis

Broadcom 2Q Revenue Climbs on AI Chip Demand

2026-06-03 23:48; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

2026-06-03 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-03 23:35; UTC

Rinkos pokalbiai

Oil Futures Fall on Possible Technical Correction -- Market Talk

2026-06-03 23:15; UTC

Rinkos pokalbiai

Uždarbis

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

2026-06-03 22:08; UTC

Karštos akcijos

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

2026-06-03 21:54; UTC

Rinkos pokalbiai

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

2026-06-03 21:18; UTC

Uždarbis

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

2026-06-03 21:15; UTC

Uždarbis

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

2026-06-03 21:13; UTC

Uždarbis

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

2026-06-03 21:13; UTC

Uždarbis

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

2026-06-03 21:12; UTC

Uždarbis

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

2026-06-03 21:09; UTC

Uždarbis

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

2026-06-03 21:03; UTC

Uždarbis

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

2026-06-03 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-03 20:43; UTC

Uždarbis

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

2026-06-03 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

2026-06-03 20:37; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

2026-06-03 20:35; UTC

Uždarbis

Broadcom Stock Falls Despite Record Results -- Barrons.com

2026-06-03 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

2026-06-03 20:17; UTC

Uždarbis

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

2026-06-03 20:17; UTC

Uždarbis

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

2026-06-03 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q Adj EPS $2.44 >AVGO

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q EPS $1.91 >AVGO

2026-06-03 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q Rev $22.19B >AVGO

Akcijų palyginimas

Kainos pokytis

MannKind Corp Prognozė

Kainos tikslas

By TipRanks

142.56% į viršų

12 mėnesių prognozė

Vidutinis 8.15 USD 142.56%

Aukščiausias 11 USD

Žemiausias 4.75 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MannKind Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių MannKind Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

144 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.